Journal Article
. 2020 Nov; 12(22):22975-23003.
doi: 10.18632/aging.104028.

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

Qiankun Zhu 1 Haiyang Ren 1 Xiaodong Li 1 Bo Qian 2 Shengjie Fan 2 Fengli Hu 2 Lishan Xu 1 Bo Zhai 1 
  • PMID: 33203790
  •     72 References


For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can reverse resistance to sorafenib. We used bioinformatics methods to identify genes whose expression was differentially induced by sorafenib and regorafenib in HCC. We identified KIF14 as an oncogene involved in the acquired resistance to sorafenib in HCC and investigated its potential as a target for reversing this resistance. Sustained exposure of resistant HCC cells to sorafenib activated the AKT pathway, which in turn upregulated KIF14 expression by increasing expression of the transcription factor ETS1. Silencing KIF14 reversed the acquired resistance to sorafenib by inhibiting AKT activation and downregulating ETS1 expression by blocking the AKT-ETS1-KIF14 positive feedback loop. Moreover, injection of siKIF14 with sorafenib suppressed growth of sorafenib-resistant HCC tumors in mice. These results demonstrate that targeting KIF14 could be an effective means of reversing sorafenib failure or strengthening sorafenib's antitumor effects.

Keywords: hepatocellular carcinoma; human kinesin family member 14; phosphatidylinositol 3-kinase/AKT signalling pathway; sorafenib; transcription factor E26 transformation specific sequence 1.

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, +18 authors, Zhongzhen Guan.
Lancet Oncol, 2008 Dec 20; 10(1). PMID: 19095497
Highly Cited.
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
Carina Hage, Sabine Hoves, +5 authors, Carola H Ries.
Hepatology, 2019 Apr 20; 70(4). PMID: 31002440
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.
S S Cao, Y S Zhen.
Cancer Chemother Pharmacol, 1989 Jan 01; 24(3). PMID: 2736709
TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
Ella Bhagyaraj, Nancy Ahuja, +4 authors, Pawan Gupta.
Cell Cycle, 2019 Nov 20; 18(24). PMID: 31739702    Free PMC article.
Inhibition of KIF14 Suppresses Tumor Cell Growth and Promotes Apoptosis in Human Glioblastoma.
Wei Huang, JunYu Wang, +4 authors, Yicheng Lu.
Cell Physiol Biochem, 2015 Nov 05; 37(5). PMID: 26536004
Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Min Wu, Xingang Liu, +6 authors, Yuan Ping.
J Control Release, 2017 Mar 18; 253. PMID: 28302581
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Shengnan Liu, Yang Du, +3 authors, Jie Tian.
Cancer Lett, 2019 Apr 01; 453. PMID: 30928380
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.
Michelle C Mendoza, E Emrah Er, John Blenis.
Trends Biochem Sci, 2011 May 03; 36(6). PMID: 21531565    Free PMC article.
Highly Cited. Review.
Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.
Josep M Llovet, Virginia Hernandez-Gea.
Clin Cancer Res, 2014 Mar 05; 20(8). PMID: 24589894
Highly Cited. Review.
Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, +22 authors, SHARP Investigators Study Group.
N Engl J Med, 2008 Jul 25; 359(4). PMID: 18650514
Highly Cited.
Advances in molecular classification and precision oncology in hepatocellular carcinoma.
Sandra Rebouissou, Jean-Charles Nault.
J Hepatol, 2020 Jan 20; 72(2). PMID: 31954487
Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma.
I Ozaki, T Mizuta, +6 authors, K Yamamoto.
Cancer Res, 2000 Dec 05; 60(22). PMID: 11103822
Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma.
Haidong Xu, Chungyoul Choe, +6 authors, Yeun-Jun Chung.
Exp Mol Med, 2014 May 24; 46. PMID: 24854087    Free PMC article.
Expression and possible role of ets-1 in hepatocellular carcinoma.
Y Ito, E Miyoshi, +6 authors, N Matsuura.
Am J Clin Pathol, 2000 Nov 09; 114(5). PMID: 11068545
Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells.
Tianhua Liu, Riqiang Liu, +4 authors, Yinkun Liu.
Oncol Lett, 2017 Jul 12; 14(1). PMID: 28693200    Free PMC article.
Molecular therapies and precision medicine for hepatocellular carcinoma.
Josep M Llovet, Robert Montal, Daniela Sia, Richard S Finn.
Nat Rev Clin Oncol, 2018 Aug 01; 15(10). PMID: 30061739
Highly Cited. Review.
Integrin α5β1-Ang1/Tie2 receptor cross-talk regulates brain endothelial cell responses following cerebral ischemia.
Defang Pang, Lu Wang, +4 authors, Longxuan Li.
Exp Mol Med, 2018 Sep 07; 50(9). PMID: 30185785    Free PMC article.
Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14.
Kamakshi Sishtla, Natalie Pitt, +7 authors, Timothy W Corson.
Sci Rep, 2018 Nov 06; 8(1). PMID: 30385851    Free PMC article.
Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific.
Allyson K Roof, Arthur Gutierrez-Hartmann.
Mol Cell Endocrinol, 2017 Apr 27; 463. PMID: 28445712
Vessel co-option in cancer.
Elizabeth A Kuczynski, Peter B Vermeulen, +2 authors, Andrew R Reynolds.
Nat Rev Clin Oncol, 2019 Mar 01; 16(8). PMID: 30816337
Highly Cited. Review.
STRING v10: protein-protein interaction networks, integrated over the tree of life.
Damian Szklarczyk, Andrea Franceschini, +11 authors, Christian von Mering.
Nucleic Acids Res, 2014 Oct 30; 43(Database issue). PMID: 25352553    Free PMC article.
Highly Cited.
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Janyaporn Phuchareon, Frank McCormick, David W Eisele, Osamu Tetsu.
Proc Natl Acad Sci U S A, 2015 Jul 08; 112(29). PMID: 26150526    Free PMC article.
Role of ETS family transcription factors in vascular development and angiogenesis.
Y Sato.
Cell Struct Funct, 2001 May 10; 26(1). PMID: 11345500
The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer.
Lixin Ma, Bo Zhai, +7 authors, Xueying Sun.
Cancer Cell Int, 2019 Oct 02; 19. PMID: 31572065    Free PMC article.
DrugBank 4.0: shedding new light on drug metabolism.
Vivian Law, Craig Knox, +15 authors, David S Wishart.
Nucleic Acids Res, 2013 Nov 10; 42(Database issue). PMID: 24203711    Free PMC article.
Highly Cited.
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Harish Potu, Luke F Peterson, +8 authors, Nicholas J Donato.
Nat Commun, 2017 Feb 16; 8. PMID: 28198367    Free PMC article.
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Mari Masuda, Wei-Yu Chen, +7 authors, Tesshi Yamada.
Mol Cell Proteomics, 2014 Mar 20; 13(6). PMID: 24643969    Free PMC article.
The role of the transcription factor Ets1 in carcinoma.
Jürgen Dittmer.
Semin Cancer Biol, 2015 Sep 24; 35. PMID: 26392377
KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer.
Zao-Zao Wang, Jie Yang, +4 authors, Xiang-Qian Su.
Int J Oncol, 2018 Sep 19; 53(5). PMID: 30226594    Free PMC article.
The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs).
Andrew M Kidger, Stephen M Keyse.
Semin Cell Dev Biol, 2016 Jan 23; 50. PMID: 26791049    Free PMC article.
Highly Cited. Review.
KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression.
Syed M Ahmed, Brigitte L Thériault, +4 authors, Stéphane Angers.
J Cell Biol, 2012 Dec 05; 199(6). PMID: 23209302    Free PMC article.
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Carolina Méndez-Blanco, Flavia Fondevila, +2 authors, José L Mauriz.
Exp Mol Med, 2018 Oct 14; 50(10). PMID: 30315182    Free PMC article.
Highly Cited. Review.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, +19 authors, Robin K Kelley.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972759    Free PMC article.
Highly Cited.
Hepatocellular Carcinoma.
Augusto Villanueva.
N Engl J Med, 2019 Apr 11; 380(15). PMID: 30970190
Highly Cited. Review.
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Peng Han, Hali Li, +7 authors, Xueying Sun.
Mol Oncol, 2017 Feb 07; 11(3). PMID: 28164434    Free PMC article.
Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.
Weibo Chen, Junsheng Yang, +3 authors, Donglin Sun.
FEBS Open Bio, 2019 Feb 15; 9(2). PMID: 30761258    Free PMC article.
DAVID: Database for Annotation, Visualization, and Integrated Discovery.
Glynn Dennis, Brad T Sherman, +4 authors, Richard A Lempicki.
Genome Biol, 2003 May 08; 4(5). PMID: 12734009
Highly Cited.
KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer.
Zhongyin Yang, Chen Li, +6 authors, Qinlong Gu.
Biochim Biophys Acta Mol Basis Dis, 2018 Nov 08; 1865(1). PMID: 30404039
The Gene Expression Omnibus Database.
Emily Clough, Tanya Barrett.
Methods Mol Biol, 2016 Mar 24; 1418. PMID: 27008011    Free PMC article.
Highly Cited.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, +19 authors, Ann-Lii Cheng.
Lancet, 2018 Feb 13; 391(10126). PMID: 29433850
Highly Cited.
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matthias S Matter, Thomas Decaens, Jesper B Andersen, Snorri S Thorgeirsson.
J Hepatol, 2013 Dec 07; 60(4). PMID: 24308993    Free PMC article.
Highly Cited. Review.
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Scott M Wilhelm, Jacques Dumas, +5 authors, Dieter Zopf.
Int J Cancer, 2010 Dec 21; 129(1). PMID: 21170960
Highly Cited.
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.
Ledu Zhou, Yun Huang, Jingdong Li, Zhiming Wang.
Med Oncol, 2009 Mar 21; 27(2). PMID: 19301157
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, +22 authors, RESORCE Investigators.
Lancet, 2016 Dec 10; 389(10064). PMID: 27932229
Highly Cited.
KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.
Stina M Singel, Crystal Cornelius, +11 authors, Jerry W Shay.
Neoplasia, 2014 May 03; 16(3). PMID: 24784001    Free PMC article.
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Peter Dietrich, Andreas Koch, +3 authors, Claus Hellerbrand.
Gut, 2017 Dec 25; 67(7). PMID: 29275358
Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression.
Haiyang Xu, Guifang Zhao, +5 authors, Ling Qi.
J Exp Clin Cancer Res, 2019 Dec 12; 38(1). PMID: 31823805    Free PMC article.
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Tan Boon Toh, Jhin Jieh Lim, +2 authors, Edward Kai-Hua Chow.
J Hepatol, 2019 Sep 22; 72(1). PMID: 31541681
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Bo Zhai, Xian Jiang, +5 authors, Xueying Sun.
Tumour Biol, 2014 Nov 25; 36(4). PMID: 25416439
Coordinated functions of Akt/PKB and ETS1 in tubule formation.
Kim R Lavenburg, Jennifer Ivey, Tien Hsu, Robin C Muise-Helmericks.
FASEB J, 2003 Oct 04; 17(15). PMID: 14525946    Free PMC article.
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Bo Zhai, Fengli Hu, +10 authors, Xueying Sun.
Mol Cancer Ther, 2014 Apr 08; 13(6). PMID: 24705351
Highly Cited.
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Fang Liu, Juxiang Cao, +6 authors, Rutao Cui.
J Invest Dermatol, 2013 Jan 25; 133(8). PMID: 23344460
The Cancer Genome Atlas Pan-Cancer analysis project.
Cancer Genome Atlas Research Network, John N Weinstein, +7 authors, Joshua M Stuart.
Nat Genet, 2013 Sep 28; 45(10). PMID: 24071849    Free PMC article.
Highly Cited.
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Bo Zhai, Fengli Hu, +6 authors, Lishan Xu.
PLoS One, 2015 Sep 19; 10(9). PMID: 26381511    Free PMC article.
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Elizabeth A Kuczynski, Melissa Yin, +9 authors, Robert S Kerbel.
J Natl Cancer Inst, 2016 Apr 10; 108(8). PMID: 27059374    Free PMC article.
Highly Cited.
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Timothy A Yap, Li Yan, +15 authors, Anthony W Tolcher.
J Clin Oncol, 2011 Oct 26; 29(35). PMID: 22025163
Highly Cited.
NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Hoi Wing Leung, Eunice Yuen Ting Lau, +10 authors, Terence Kin Wah Lee.
Cancer Lett, 2020 Feb 18; 476. PMID: 32061952
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.
Bo Zhai, Xue-Ying Sun.
World J Hepatol, 2013 Jul 31; 5(7). PMID: 23898367    Free PMC article.
Suppression of KIF14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome.
Tao Yang, Xian-Bo Zhang, Zhi-Min Zheng.
Cancer Sci, 2013 Feb 19; 104(5). PMID: 23414349    Free PMC article.
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Jiejie Dong, Bo Zhai, +3 authors, Jun Xu.
PLoS One, 2017 Sep 22; 12(9). PMID: 28934275    Free PMC article.
Cytoscape: software for visualization and analysis of biological networks.
Michael Kohl, Sebastian Wiese, Bettina Warscheid.
Methods Mol Biol, 2010 Nov 11; 696. PMID: 21063955
Highly Cited.
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.
Maria Kissel, Sandra Berndt, +7 authors, Dieter Zopf.
Oncotarget, 2018 Jan 02; 8(63). PMID: 29291014    Free PMC article.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2018 Sep 13; 68(6). PMID: 30207593
Highly Cited.
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Carmen Oi Ning Leung, Man Tong, +8 authors, Terence Kin Wah Lee.
Hepatology, 2019 Oct 15; 72(1). PMID: 31610028
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Dali Zhao, Bo Zhai, +9 authors, Xueying Sun.
Cell Signal, 2014 Feb 04; 26(5). PMID: 24486412
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Scott M Wilhelm, Christopher Carter, +23 authors, Pamela A Trail.
Cancer Res, 2004 Oct 07; 64(19). PMID: 15466206
Highly Cited.
Molecular therapies for HCC: Looking outside the box.
Sandrine Faivre, Lorenza Rimassa, Richard S Finn.
J Hepatol, 2020 Jan 20; 72(2). PMID: 31954496
A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Stina Mui Singel, Crystal Cornelius, +4 authors, Jerry W Shay.
Clin Cancer Res, 2013 Mar 13; 19(8). PMID: 23479679    Free PMC article.
Ets-1 facilitates nuclear entry of NFAT proteins and their recruitment to the IL-2 promoter.
Hsiao-Wei Tsao, Tzong-Shyuan Tai, +4 authors, I-Cheng Ho.
Proc Natl Acad Sci U S A, 2013 Sep 11; 110(39). PMID: 24019486    Free PMC article.
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Jiang Chen, Renan Jin, +10 authors, Xiujun Cai.
Cancer Lett, 2015 Jul 15; 367(1). PMID: 26170167
Highly Cited. Review.
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Jennifer D Cohen, Kimberly Y Tham, +3 authors, Serrine S Lau.
Toxicol Sci, 2011 Jun 23; 122(2). PMID: 21693435    Free PMC article.
ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Zhiyi Shao, Yibo Li, +10 authors, Yingjie Guo.
Pharmacol Res, 2018 Aug 17; 135. PMID: 30114438